This is a standard, non-eventful proxy filing. Traders should expect no immediate market reaction. Monitor for any unexpected proposals in the full proxy, though none are indicated here.
JNJ drugs
JNJ drug pipeline →- ▲ DARZALEX 4/10 Approved (multiple FDA-approved multiple-myeloma indications); additional label-expansion Phase 3 studies completed.
- ◆ IMAAVY 4/10 Approved (first indication); NDA under FDA review for wAIHA
- ● SPRAVATO 4/10 Approved
- ▲ TREMFYA 4/10 Approved (marketed); BLA 761061 with multiple supplemental approvals; further Phase 3 label-expansion studies ongoing/co
- ▲ CARVYKTI 3/10 Approved (marketed); ongoing Phase 2/3 studies
- 12 more · All JNJ drugs, catalysts & trials →
How the stock moved after the report
NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Mar 11 $242.95entry
- T+1 · 8mo ago −0.35%α +1.13% · $242.10
- T+5 · 8mo ago −2.37%α −0.18% · $237.20
- T+20 · 7mo ago −0.71%α −1.24% · $241.22
- T+60 · 5mo ago −8.11%α −19.63% · $223.24
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Johnson & Johnson filed a definitive proxy statement (DEFA14A) for its upcoming shareholder meeting. The filing is routine and filed by the company (registrant), disclosing items such as director elections and executive compensation. No activist campaign or contested vote is indicated. Market data shows analyst sentiment is mixed (59% bullish), with minimal recent insider selling.
Key Facts
- Filing is a routine DEFA14A proxy statement filed by Johnson & Johnson.
- Filed as 'Definitive Proxy Statement', indicating standard disclosure for an upcoming shareholder vote.
- Items likely include election of directors, executive compensation, and other standard corporate governance matters.
- No indication of a dissident party or activist campaign; this is a standard management solicitation.
- Recent insider activity shows only a minor sell transaction by a Congressman.
Financial Impact
No direct financial impact from the filing itself.
Risk Factors
- The actual proxy document (not fully provided) could contain unexpected items, though the filing type and headers suggest it's routine.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| DEFA14A Filing (Primary) | 0000200406-26-000065 |
| Document: 0000200406-26-000065-index-headers.html | 0000200406-26-000065 |
| Document: 0000200406-26-000065-index.html | 0000200406-26-000065 |
| Document: 0000200406-26-000065.txt | 0000200406-26-000065 |
Track record
21 reports on JNJ
4 of 5 bullish or bearish reports moved the stock their way by T+60. Best: +13.24% at T+60 after the May 13, 2026 report. 6 of 6 went positive at some point.
Filters
- Nov 16, 2026today Institutional Cluster Mixed 3/10 Entry $289.75 Now $282.55 −2.48% settles Feb 12
- Nov 12, 20264d ago 144 Neutral 2/10 Entry $283.52 Now $282.55 −0.34% settles Feb 10
- Oct 13, 20264w ago 8-K Mixed 6/10 Entry $248.61 Now $282.55 +13.65% settles Jan 8
- Sep 30, 20266w ago Court Ruling Bullish 6/10 Entry $258.66 Now $282.55 +9.24% settles Dec 28
- Sep 24, 20267w ago Court Ruling Neutral 3/10 Entry $271.22 Now $282.55 +4.18% settles Dec 21
- Sep 9, 20269w ago Court Ruling Neutral 1/10 Entry $266.35 Now $282.55 +6.08% settles Dec 4
- Aug 18, 202612w ago Insider Cluster Neutral 2/10 Entry $273.41 to $283.52 Now $282.55 +3.34% ▲ +3.70% +5.25% vs SPY
- Aug 14, 202613w ago Insider Cluster Neutral 2/10 Entry $262.37 to $280.78 Now $282.55 +7.69% ▲ +7.02% +9.96% vs SPY
- Aug 7, 202614w ago Insider Cluster Neutral 3/10 Entry $261.81 to $266.17 Now $282.55 +7.92% ▲ +1.67% +4.08% vs SPY
- Aug 7, 202614w ago Court Ruling Bearish 4/10 Entry $261.81 to $266.17 Now $282.55 −7.92% ▼ −1.67% −4.08% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers